Parkinson's Disease Mechanisms and Treatments
Research Guide

α-Synuclein is the main component of Lewy bodies in Parkinson's disease, as shown in 'α-Synuclein in Lewy bodies' (Spillantini et al., 1997). Mutations in the α-synuclein gene cause familial Parkinson's disease, per 'Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease' (Polymeropoulos et al., 1997). These findings establish α-synuclein aggregation as a core pathological mechanism.

Brain pathology in sporadic Parkinson’s disease progresses through six stages starting in the brainstem, as described in 'Staging of brain pathology related to sporadic Parkinson’s disease' (Braak et al., 2002). Early stages involve the dorsal motor nucleus of the glossopharyngeal and vagal nerves, advancing to substantia nigra and neocortex. This staging correlates with clinical symptom onset and severity.

Clinical diagnosis of idiopathic Parkinson's disease by neurologists achieves 76% accuracy confirmed by nigral Lewy bodies on pathology, according to 'Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases' (Hughes et al., 1992). Of 100 prospectively diagnosed cases, 76 met pathological criteria. This underscores the need for supportive criteria like those in Postuma et al. (2015).

The MDS-UPDRS is a revised scale with four parts assessing non-motor experiences of daily living, motor experiences of daily living, motor examination, and motor complications, as presented in 'Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results' (Goetz et al., 2008). It improves upon the original UPDRS through clinimetric testing. Clinicians and researchers use it for symptom tracking and trial outcomes.

The Movement Disorder Society criteria for Parkinson's disease diagnosis include bradykinesia plus rigidity or rest tremor, with supportive biomarkers, as outlined in 'MDS clinical diagnostic criteria for Parkinson's disease' (Postuma et al., 2015). These criteria are for clinical research and practice, benchmarked against expert consensus. They incorporate neuroimaging and response to dopaminergic therapy.

L-DOPA administration replenishes depleted dopamine to alleviate motor symptoms, serving as the mainstay symptomatic treatment. The MDS-UPDRS quantifies treatment response in clinical settings. Ongoing research targets disease modification beyond symptom relief.